Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 634-640

  Titier, Karine ^a   Picard, Stéphane ^a   Ducint, Dominique ^a   Teilhet, Emmanuelle ^a   Moore, Nicholas ^a   Berthaud, Patrice ^b   Mahon, François Xavier ^a   Molimard, Mathieu ^a  

^a HÔPITAL PELLEGRIN   (France)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Imatinib; Liquid chromatography mass spectrometry; Quantification

Indexed keywords

ACETONITRILE; AMMONIUM FORMATE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACCURACY; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG MONITORING; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID LIQUID EXTRACTION; PATIENT COMPLIANCE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REACTION ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG STABILITY; HUMANS; PIPERAZINES; PYRIMIDINES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 26444595727     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000175973.71140.91     Document Type: Article

References (14)

1. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med. 2002;346:683-693.
2. Roskoski R Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun. 2003;309:709-717.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
4. Mahon FX. Chronic myeloid leukemia and tyrosine kinase inhibitors. Rev Med Interne. 2001;22:894-899.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
6. Guetens G, De Boeck G, Highley M, et al. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2003;1020:27-34.
7. Bakhtiar R, Lohne J, Ramos L, et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2002;768:325-340.
8. Schleyer E, Pursche S, Kohne CH, et al. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B Anal Technol Biomed Life Sci. 2004;799:23-36.
9. Vivekanand VV, Sreenivas Rao D, Vaidyanathan G, et al. A validated LC method for imatinib mesylate. J Pharm Biomed Anal. 2003;33:879-889.
10. Parise RA, Ramanathan RK, Hayes MJ, et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2003;791:39-44.
11. Bakhtiar R, Khemani L, Hayes M, et al. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2002;28:1183-1194.
12. King R, Bonfiglio R, Fernandez-Metzler C, et al. Mechanistic investigation of ionization suppression in electrospray ionization. J Am Soc Mass Spectrom. 2000;11:942-950.
13. Shen JX, Motyka RJ, Roach JP, et al. Minimization of ion suppression in LC-MS/MS analysis through the application of strong cation exchange solid-phase extraction (SCX-SPE). J Pharm Biomed Anal. 2005;37:359-367.
14. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935-942.